This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mekhail, T. M. Articles by Bukowski, R. Search for Related Content PubMed PubMed Citation Articles by Mekhail, T. M. Articles by Bukowski, R. Social Bookmarking                            What's this?

Validation and Extension of the Memorial Sloan-Kettering Prognostic Factors Model for Survival in Patients With Previously Untreated Metastatic Renal Cell Carcinoma

From the Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH

Address reprint requests to and reprints to: Tarek M. Mekhail, MD, Experimental Therapeutics, Taussig Cancer Center, Taussig Cancer Center R-35, The Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195; e-mail: mekhait{at}cc.ccf.org

PURPOSE: To validate the Motzer et al prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma (RCC) and to identify additional independent prognostic factors.

PATIENTS AND METHODS: Data were collected on 353 previously untreated metastatic RCC patients enrolled onto clinical trials between 1987 and 2002.

RESULTS: Four of the five prognostic factors identified by Motzer were independent predictors of survival. In addition, prior radiotherapy and presence of hepatic, lung, and retroperitoneal nodal metastases were found to be independent prognostic factors. Using the number of metastatic sites as surrogate for individual sites (none or one v two or three sites), Motzer’s definitions of risk groups were expanded to accommodate these two additional prognostic factors. Using this expanded criteria, favorable risk is defined as zero or one poor prognostic factor, intermediate risk is two poor prognostic factors, and poor risk is more than two poor prognostic factors. According to Motzer’s definitions, 19% of patients were favorable risk, 70% were intermediate risk, and 11% were poor risk; median overall survival times for these groups were 28.6, 14.6, and 4.5 months, respectively (P < .0001). Using the expanded criteria, 37% of patients were favorable risk, 35% were intermediate risk, and 28% were poor risk; median overall survival times of these groups were 26.0, 14.4, and 7.3 months, respectively (P < .0001).

CONCLUSION: These data validate the model described by Motzer et al. Additional independent prognostic factors identified were prior radiotherapy and sites of metastasis. Incorporation of these additional prognostic factors into the Motzer et al model can help better define favorable risk, intermediate risk, and poor risk patients.

Presented in part at the 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31-June 3, 2003.

Authors’ disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T. B. Dorff, A. Goldkorn, and D. I. Quinn Review: Targeted therapy in renal cancer Therapeutic Advances in Medical Oncology, November 1, 2009; 1(3): 183 - 205. [Abstract] [PDF]

				A. J. Montero, C. M. Diaz-Montero, R. E. Millikan, J. Liu, K.-A. Do, S. Hodges, E. Jonasch, B. W. McIntyre, P. Hwu, and N. Tannir Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-{alpha}: association of pretreatment serum levels with survival Ann. Onc., October 1, 2009; 20(10): 1682 - 1687. [Abstract] [Full Text] [PDF]

				B. I. Rini Metastatic Renal Cell Carcinoma: Many Treatment Options, One Patient J. Clin. Oncol., July 1, 2009; 27(19): 3225 - 3234. [Abstract] [Full Text] [PDF]

				R. L. Barros Costa Review Article: Targeted Therapy: Comprehensive Review American Journal of Hospice and Palliative Medicine, April 1, 2009; 26(2): 137 - 146. [Abstract] [PDF]

				J. Kim, E. Jonasch, A. Alexander, J. D. Short, S. Cai, S. Wen, D. Tsavachidou, P. Tamboli, B. A. Czerniak, K. A. Do, et al. Cytoplasmic Sequestration of p27 via AKT Phosphorylation in Renal Cell Carcinoma Clin. Cancer Res., January 1, 2009; 15(1): 81 - 90. [Abstract] [Full Text] [PDF]

				S. Biswas, J. Kelly, and T. Eisen Cytoreductive Nephrectomy in Metastatic Clear-Cell Renal Cell Carcinoma: Perspectives in the Tyrosine Kinase Inhibitor Era Oncologist, January 1, 2009; 14(1): 52 - 59. [Abstract] [Full Text] [PDF]

				J. A. Garcia and D. Danielpour Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies Mol. Cancer Ther., June 1, 2008; 7(6): 1347 - 1354. [Abstract] [Full Text] [PDF]

				R. M. Bukowski How I Treat Renal Cell Carcinoma J. Oncol. Pract, May 1, 2008; 4(3): 150 - 152. [Full Text] [PDF]

				N. S. Vasudev, J. E. Brown, S. R. Brown, R. Rafiq, R. Morgan, P. M. Patel, D. O'Donnell, P. Harnden, M. Rogers, K. Cocks, et al. Prognostic Factors in Renal Cell Carcinoma: Association of Preoperative Sodium Concentration with Survival Clin. Cancer Res., March 15, 2008; 14(6): 1775 - 1781. [Abstract] [Full Text] [PDF]

				B. I. Rini Temsirolimus, an Inhibitor of Mammalian Target of Rapamycin Clin. Cancer Res., March 1, 2008; 14(5): 1286 - 1290. [Full Text] [PDF]

				T. K. Choueiri, A. Plantade, P. Elson, S. Negrier, A. Ravaud, S. Oudard, M. Zhou, B. I. Rini, R. M. Bukowski, and B. Escudier Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma J. Clin. Oncol., January 1, 2008; 26(1): 127 - 131. [Abstract] [Full Text] [PDF]

				W. K. Rathmell, W. M. Stadler, and B. I. Rini Rational Therapeutic Choices and Strategies for Patients with Metastatic Renal Cancer ASCO Educational Book, January 1, 2008; 2008(1): 192 - 198. [Abstract] [Full Text] [PDF]

				G. Hudes, M. Carducci, P. Tomczak, J. Dutcher, R. Figlin, A. Kapoor, E. Staroslawska, J. Sosman, D. McDermott, I. Bodrogi, et al. Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma N. Engl. J. Med., May 31, 2007; 356(22): 2271 - 2281. [Abstract] [Full Text] [PDF]

				J. A. Garcia and B. I. Rini Recent Progress in the Management of Advanced Renal Cell Carcinoma CA Cancer J Clin, March 1, 2007; 57(2): 112 - 125. [Abstract] [Full Text] [PDF]

				T. Choueiri, B. Rini, J. Garcia, R. Baz, R. Abou-Jawde, S. Thakkar, P Elson, T. Mekhail, M Zhou, and R. Bukowski Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma Ann. Onc., February 1, 2007; 18(2): 249 - 255. [Abstract] [Full Text] [PDF]

				R. J. Motzer, T. E. Hutson, P. Tomczak, M. D. Michaelson, R. M. Bukowski, O. Rixe, S. Oudard, S. Negrier, C. Szczylik, S. T. Kim, et al. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma N. Engl. J. Med., January 11, 2007; 356(2): 115 - 124. [Abstract] [Full Text] [PDF]

				J. S. Lam, A. Breda, A. S. Belldegrun, and R. A. Figlin Evolving Principles of Surgical Management and Prognostic Factors for Outcome in Renal Cell Carcinoma J. Clin. Oncol., December 10, 2006; 24(35): 5565 - 5575. [Abstract] [Full Text] [PDF]

				M. Parton, M. Gore, and T. Eisen Role of Cytokine Therapy in 2006 and Beyond for Metastatic Renal Cell Cancer J. Clin. Oncol., December 10, 2006; 24(35): 5584 - 5592. [Abstract] [Full Text] [PDF]

				R. J. Motzer and R. M. Bukowski Targeted Therapy for Metastatic Renal Cell Carcinoma J. Clin. Oncol., December 10, 2006; 24(35): 5601 - 5608. [Abstract] [Full Text] [PDF]

				S. E. Eggener, O. Yossepowitch, J. A. Pettus, M. E. Snyder, R. J. Motzer, and P. Russo Renal Cell Carcinoma Recurrence After Nephrectomy for Localized Disease: Predicting Survival From Time of Recurrence J. Clin. Oncol., July 1, 2006; 24(19): 3101 - 3106. [Abstract] [Full Text] [PDF]

				F. Donskov and H. von der Maase Impact of Immune Parameters on Long-Term Survival in Metastatic Renal Cell Carcinoma J. Clin. Oncol., May 1, 2006; 24(13): 1997 - 2005. [Abstract] [Full Text] [PDF]